Clinical trials: Healthy Japanese
Healthy
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects
The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose to Japanese healthy subjects.
- Trial name
- NCT00972049
- Testing
- AZD2516
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects
This is a single ascending dose, open-label study that will evaluate the pharmacokinetics and safety of the AG-221 compound in normal, healthy volunteer male subjects (both Japanese and Caucasian).
- Trial name
- NCT02387866
- Testing
- AG-221
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy
A Study of JNJ-61393215 in Healthy Japanese Male Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single dose administrations of JNJ-61393215 in Japanese healthy adult male participants.
- Trial name
- NCT04713930
- Testing
- JNJ-61393215
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Healthy Study Participants
A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
The purpose of the study is to estimate the relative bioavailability of 2 new UCB0599 formulations under elevated and normal gastric pH conditions in healthy participants (Part A) and to asess the safety, tolerability and…
- Trial name
- NCT05845645
- Testing
- UCB0599, Esomeprazole
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy
Daclizumab Japanese PK Study
The primary objective of the study is to evaluate the pharmacokinetic (PK) profile of BIIB019 (Daclizumab High Yield Process; DAC HYP) administered as a single subcutaneous (SC) dose (75 mg or 150 mg) Japanese and Caucasian adult…
- Trial name
- NCT01929746
- Testing
- BIIB019 subcutaneous injection
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Biogen
Obesity
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body.
- Trial name
- NCT06542536
- Testing
- Monlunabant
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Infections, Rotavirus, Rotavirus Vaccines
Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants
This study is undertaken to provide the regulatory authorities in Japan with immunogenicity, efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus [HRV] vaccine, given as a 2-dose primary vaccination, in…
- Trial name
- NCT00480324
- Testing
- Rotarix
- Where
- 20 sites in Japan
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease
Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
This is a Phase 1, randomised, blinded, placebo controlled, study designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity response to single and multiple doses of MEDI3506.
- Conditions
- Part I (SAD) - Healthy Participants, Part II (MAD) - Chronic Obstructive Pulmonary Disease, Part III (J-SD) - Healthy Japanese Participants
- Trial name
- NCT03096795
- Testing
- MEDI3506
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy
A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated
The primary objective of the trial is to investigate the safety and tolerability of BI 690517 in healthy Japanese male subjects following oral administration of multiple rising doses over 14 days.
- Trial name
- NCT03608072
- Testing
- BI 690517
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects
To assess the safety and tolerability of ascending single SC and IV doses of ATN-103 in healthy Japanese male subjects.
- Trial name
- ATN-103 (NCT00916110)
- Testing
- ATN-103
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ablynx, a Sanofi company
Healthy
Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)
To demonstrate the bioequivalence of a Levetiracetam dry syrup (50% (500mg/1000mg)) versus Levetiracetam 500 mg oral tablet, used as reference, after single dose administration in healthy Japanese subjects.
- Trial name
- NCT00985348
- Testing
- Levetiracetam (Keppra)
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Healthy
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants
The purpose of this study is to evaluate the safety of JNJ-42847922 following single oral administration.
- Trial name
- NCT02555124
- Testing
- JNJ-42847922, 5 mg, JNJ-42847922, 20 mg, JNJ-42847922, 40 mg
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Healthy Subjects
Bioequivalence Study of SB797620 in Healthy Japanese Volunteers
This study will test whether the Drug levels in plasma after combination formulation tablet dosing (SB797620) and separate formulation tablets dosing (rosiglitazone and glimepiride) to Japanese Healthy volunteer would be the same…
- Trial name
- NCT00549263
- Testing
- SB797620
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
Dolutegravir (DTG), a human immunodeficiency virus (HIV)-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are each approved in the United States (US), European…
- Trial name
- NCT03984838
- Testing
- JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Chronic Pain
AZD1386 Japanese Multiple Ascending Dosing Study
This is a single centre, double-blind, randomised, parallel group, placebo controlled study to assess the safety, tolerability and pharmacokinetics of AZD1386 when given as multiple doses to 32 (24 healthy young and 8 healthy…
- Trial name
- JMAD (NCT00736658)
- Testing
- AZD1386
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants
The primary objective of this study is to determine the bioequivalence of ABP 501 (subcutaneous [SC] injection) compared to adalimumab (SC injection) as assessed principally by the area under the serum concentration-time curve…
- Trial name
- NCT05995691
- Testing
- ABP 501, Adalimumab
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males
The purpose of this study is to evaluate the pharmacokinetic profile of Esomeprazole (D961H) during repeated oral administration with and without co-administration of loxoprofen and the pharmacokinetic profile of loxoprofen…
- Trial name
- NCT00676117
- Testing
- Esomeprazole (D961H), Loxoprofen
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
This study is designed to evaluate the influence of ethnic factors on the safety, tolerability, and pharmacokinetics (PK) of BGB-23339 after multiple dosing under fasting condition in healthy Japanese and Caucasian participants.
- Trial name
- NCT05387668
- Testing
- BGB-23339
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- BeiGene
Healthy
Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants
The purpose of this study is to investigate the steady-state pharmacokinetics (PK) of simeprevir (SMV), odalasvir (ODV) and AL-335 (and its metabolites ALS-022399 and ALS 022227), when these drugs are co-administered in healthy…
- Trial name
- NCT02824315
- Testing
- AL-335, Odalasvir (ODV), Simeprevir (SMV)
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC